Recalls And Multiple Market Challenges Test Philips’ Resilience Into Q1
Philips’ revenues contraction in the first quarter of 2022 was less than feared and its order book remains impressive, but challenges presented by the recall program and generic post-COVID factors for the year ahead remain substantial.
You may also be interested in...
US Regulatory Roundup, March 2022: QMSR Draft Highlights; More Headaches For Philips; Essure Wreaks Havoc
The US FDA’s proposed Quality Management System Regulation, more ventilator recall headaches for Philips, and ongoing problems with Bayer’s Essure birth control device topped our list of most-read articles in March.
Medical support is arriving in Ukraine in more significant volumes, and rules facilitating medical product use continue to be put in place by the government against the backdrop of the Russian invasion and worsening humanitarian tragedy.
3M’s health care company spin-off is expected to be launched in the first half of 2024 under the name Solventum.